Application of the whole-body Positron Emission Tomography (PET) to the diagnosis of the progression of the digestive orgen cancer and the evaluation of the efficacy of anti-cancer agents.

全身正电子发射断层扫描（PET）在消化器官癌症进展诊断和抗癌药物疗效评价中的应用。

基本信息

批准号：
13670910
负责人：
YOSHIOKA Takashi
金额：
$ 1.54万
依托单位：
Tohoku University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2001
资助国家：
日本
起止时间：
2001 至 2002
项目状态：
已结题

项目摘要

The development of positron emission tomomgraphy (PET) has made it possible to obtain metabolic image of living bodies with proper tracers. Fluorine-18-2-deoxy-2-fluoro-D-glucose (FDG), a structural analo like glucose, is a PET tracer for the glycolytic metabolism and has been widely used in oncology because increased glycolysis is one of the most important characteristics of cancer cells.PET with FDG (FDG-PET) has been used to image successfully various kinds of hum an neoplasms, however, its application for stomach neoplasms has been limited. The first aim of this study was to evaluate the visual diagnostic accuracy of FDG-PET for the diagnosis of the progressions in patients with aidvanced, metastatic or recurrent gastric cancer and to generate semiquantitative values for lesions.FDG-PET scans were obtained on 42 patients : 20 patients with a PT931/04 scanner that covers 15 cm above and below the targeted lesion, and 22 patients with a SET 2400W scanner that images entire body A II … More PET images were interpreted visually, and tracer uptakes were quantitated as standardized uptake values (SUYs) on SET 2400W images. The sensitivity, specitivity, and accuracy as a whole were as follow 71%, 74%, and 73%, respectively, with the SWT2400W scanner and 47%, 79%, and 62%, redspectively, with the PT931/04 scanner. Values were high for primary lesions, liver, lymphnode, and lung metastases, bu were low for bone metastases, ascites, peritonitis, and pleuritis carcinom atoses. Comparing SUVs and histologic finding for 17 untreated patients, values for well-differentiated and moderately differentiated adenocarcinom as were higher than poorly differentiated adenocarcinomas as and signet ring cell carcinomas. Our results indicate that FDG-PET is a useful diagnostic modality for the advanced, metastatic, orrecurrent gastric cancer but not for detecting bone metastases, peritinitis, or pleuritis carcinom atoses. FDG uptake by gastric cancers is relatively high but does not parallel histopathologic features of malignancy.The second aim of this study is to clarify if PET is useful for the evaluation for the efficacy of molecular targeted agents, but data has not been obtained yet. Less

正电子发射断层扫描（PET）的发展使得利用适当的示踪剂获得活体的代谢图像成为可能，氟-18-2-脱氧-2-氟-D-葡萄糖（FDG）是一种结构类似物葡萄糖。用于糖酵解代谢的 PET 示踪剂，已广泛应用于肿瘤学，因为糖酵解增加是癌细胞最重要的特征之一。FDG PET (FDG-PET) 已被广泛应用FDG-PET 用于成功地对各种人类肿瘤进行成像，然而，其在胃肿瘤中的应用受到限制。本研究的首要目的是评估 FDG-PET 在诊断晚期、晚期患者进展方面的视觉诊断准确性。转移性或复发性胃癌，并生成病变的半定量值。对 42 名患者进行了 FDG-PET 扫描：20 名患者使用 PT931/04 扫描仪覆盖肿瘤上下 15 厘米22 名患者使用 SET 2400W 扫描仪对全身进行成像，对 PET 图像进行视觉解读，并将示踪剂摄取定量为 SET 2400W 图像上的标准化摄取值 (SUY)。使用 SWT2400W 扫描仪时，整体准确率分别为 71%、74% 和 73%，以及 47%，与 PT931/04 扫描仪相比，原发灶、肝脏、淋巴结和肺转移的值分别为 79% 和 62%，而骨转移、腹水、腹膜炎和胸膜炎癌的值较低。 17 名未经治疗的患者的 SUV 和组织学发现，高分化和中分化腺癌的值高于我们的结果表明，FDG-PET 对于晚期、转移性或复发性胃癌是一种有用的诊断方式，但不能用于检测胃癌摄取 FDG 的骨转移、腹膜炎或胸膜炎。相对较高，但与恶性肿瘤的组织病理学特征不平行。本研究的第二个目的是阐明 PET 是否有助于评估分子靶向药物的疗效，但尚未获得较少的数据。